Background The association between coronavirus infection 2019 (COVID-19) and
thrombosis has been explicitly shown through numerous reports that demonstrate high rates …

Objective: The majority of patients with COVID-19 showed mild symptoms. However,
approximately 5% of them were critically ill and require intensive care unit admission for …

Introduction: COVID-19 is characterized by a procoagulant state that increases the risk of
venous and arterial thrombosis. The dose of anticoagulants in patients with severe COVID …

Coagulopathy represents one of the most important determinants of morbidity and mortality
in coronavirus disease-19 (COVID-19). Whether standard thromboprophylaxis is sufficient or …

Introduction: Thromboembolic complications affect a large proportion of patients with critical
COVID-19, and it may be associated with an increased risk of death. It has been …

Background It is still unclear if patients with community-acquired pneumonia (CAP) and
coronavirus disease 2019 (COVID-19) have different rate, typology, and impact of …

Introduction: Thrombosis and bleeding are recognized complications of the novel
coronavirus infection (COVID-19), with a higher incidence described particularly in the …

Background Thrombotic events can increase the COVID-19 associated disease mortality.
The administration of prophylactic anticoagulants had been shown to decrease the …

Background: Many studies have evaluated thromboembolic events in COVID-19 patients,
and most of them have reported a high estimation of the prevalence of such events. The …

Coronavirus disease 2019 (COVID-19) is a new viral disease complicating with acute
thrombophylic conditions, probably also via an inflammatory burden. Anticoagulants are …